Celgene

Morphosys to take on CAR-Ts in NHL with promising antibody
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
MorphoSys
Celgene
Revlimid
non-Hodgkin lymphoma
clinical trials
tafasitamab
Flag link:
After years of delays, NICE backs Celgene’s Revlimid in first-line MM
After years of delays, NICE backs Celgene’s Revlimid in first-line MM
Pharmaforum
Celgene
Revlimid
Multiple Myeloma
NICE
NHS
England
Flag link:
Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma
Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma
Pharmaceutical Business Review
Celgene
Pomalyst
breakthrough therapies
Kaposi's Sarcoma
Flag link:
Biotech Companies Provide High Median Salaries, Analysis Shows
Biotech Companies Provide High Median Salaries, Analysis Shows
BioSpace
salaries
biotech
Incyte
Celgene
Vertex Pharmaceuticals
Flag link:
Don't worry about our $19B bond issue, BMS says. With Celgene, we'll have the cash to pay it off
Don't worry about our $19B bond issue, BMS says. With Celgene, we'll have the cash to pay it off
Fierce Pharma
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses
Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses
Fierce Biotech
Celgene
Bluebird Bio
bb2121
cell therapy
CAR-T
Multiple Myeloma
Flag link:
Seattle life sciences industry has strength in numbers despite uncertainty
Seattle life sciences industry has strength in numbers despite uncertainty
Bizjournals
Seattle
Juno Therapeutics
Celgene
Flag link:
Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming
Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming
Motley Fool
earnings
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay
Investors to AbbVie, J&J, Merck and more: Fork over info on pricing and executive pay
Fierce Pharma
AbbVie
Celgene
JNJ
Merck
Pfizer
Vertex Pharmaceuticals
investors
executive pay
Flag link:
Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
CNBC
M&A
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Flag link:
The Bristol-Celgene merger is approved. Here are 8 challenges ahead
The Bristol-Celgene merger is approved. Here are 8 challenges ahead
Stat
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Big Pharma come together for better drug side effect detection
Big Pharma come together for better drug side effect detection
Pharma Times
side effects
adverse events
Pfizer
Roche
Takeda
Eli Lilly
Bristol-Myers Squibb
Gilead Sciences
Alexion
Celgene
International Working Group on Signal Detection and Management in Pharmacovigilance
pharmacovigilance
Flag link:
Celgene and Acceleron Submit BLA for Luspatercept
Celgene and Acceleron Submit BLA for Luspatercept
CP Wire
Celgene
Acceleron
luspatercept
myelodysplastic syndrome
beta thalassemia
Flag link:
Celgene and Acceleron Submit BLA for Luspatercept
Celgene
Acceleron
luspatercept
Flag link:
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Endpoints
Bristol-Myers Squibb
Celgene
Morgan Stanley
M&A
Flag link:
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
Endpoints
Bristol-Myers Squibb
Celgene
M&A
Starboard
Giovanni Caforio
Flag link:
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Stat
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
TheStreet.com
SEC
FTC
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Fierce Pharma
Bristol-Myers Squibb
Celgene
investors
M&A
Flag link:

Pages